Overview
Congenital hyperinsulinism (CHI) is characterized by inappropriate insulin secretion leading to severe hypoglycemia, often due to dysfunction of ATP-sensitive potassium channels (KATP) in pancreatic beta-cells. It can manifest as diffuse or focal disease, with genetic mutations in genes like SUR1, KIR6.2, and GLUD1 implicated in its pathogenesis 12456.Diagnosis
Clinical Presentation: Profound hypoglycemia, often with neuroglycopenic symptoms 12.
Genetic Testing: Mutations in SUR1 (ABCC8), KIR6.2 (KCNJ11), and GLUD1 genes 12456.
Imaging: Focal CHI identified via MRI with arterial secretagogue stimulation 2.
Biochemical Tests: Elevated insulin and low blood glucose levels during hypoglycemia 12.
Histological Examination: Diffuse CHI shows generalized beta-cell hyperplasia; focal CHI reveals localized lesions 2.
GDH Activity: Reduced GTP sensitivity in GLUD1-related cases 46.Management
First-Line Treatments:
- Diazoxide: Initial pharmacological intervention to inhibit insulin secretion 12.
Adjunctive Treatments:
- Surgical Intervention: Subtotal pancreatectomy for refractory cases 27.
- Glucose Infusion: Continuous glucose infusion to maintain normoglycemia 1.
- Leucine-Restricted Diet: Beneficial in GLUD1-related hyperinsulinism 4.
- Somatostatin Analogues: Octreotide for additional control of insulin secretion 1.Special Populations
Pediatrics: Neonatal and infancy-onset hypoglycemia requiring early intervention 124.
Syndromal Disorders: Hyperinsulinism associated with complex syndromes like Beckwith-Wiedemann syndrome may necessitate tailored management 3.Key Recommendations
Genetic Testing for Diagnosis: Perform genetic testing for mutations in SUR1, KIR6.2, and GLUD1 genes in patients with suspected CHI (Evidence: Strong 12456).
Initial Use of Diazoxide: Initiate treatment with diazoxide for managing hyperinsulinism (Evidence: Strong 12).
Consider Surgical Options for Refractory Cases: Evaluate subtotal pancreatectomy in patients unresponsive to medical management (Evidence: Moderate 27).
Tailored Dietary Management: Implement leucine-restricted diets in GLUD1-related hyperinsulinism (Evidence: Moderate 4).
Continuous Glucose Monitoring: Utilize continuous glucose monitoring to manage hypoglycemia effectively (Evidence: Expert opinion).References
1 Sivaprasadarao A, Taneja TK, Mankouri J, Smith AJ. Trafficking of ATP-sensitive potassium channels in health and disease. Biochemical Society transactions 2007. link
2 Giurgea I, Bellanné-Chantelot C, Ribeiro M, Hubert L, Sempoux C, Robert JJ et al.. Molecular mechanisms of neonatal hyperinsulinism. Hormone research 2006. link
3 Meissner T, Rabl W, Mohnike K, Scholl S, Santer R, Mayatepek E. Hyperinsulinism in syndromal disorders. Acta paediatrica (Oslo, Norway : 1992) 2001. link
4 De Lonlay P, Benelli C, Fouque F, Ganguly A, Aral B, Dionisi-Vici C et al.. Hyperinsulinism and hyperammonemia syndrome: report of twelve unrelated patients. Pediatric research 2001. link
5 Miki Y, Taki T, Ohura T, Kato H, Yanagisawa M, Hayashi Y. Novel missense mutations in the glutamate dehydrogenase gene in the congenital hyperinsulinism-hyperammonemia syndrome. The Journal of pediatrics 2000. link90052-0)
6 Stanley CA, Fang J, Kutyna K, Hsu BY, Ming JE, Glaser B et al.. Molecular basis and characterization of the hyperinsulinism/hyperammonemia syndrome: predominance of mutations in exons 11 and 12 of the glutamate dehydrogenase gene. HI/HA Contributing Investigators. Diabetes 2000. link
7 Sempoux C, Poggi F, Brunelle F, Saudubray JM, Fekete C, Rahier J. Nesidioblastosis and persistent neonatal hyperinsulinism. Diabete & metabolisme 1995. link